1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6322EFFEF79F15E8A65257EA600428F75
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-role-in-health-economics-outcomes-research-within-oncology
18
19
2098.80.143.34
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Health Outcomes

Medical Affairs’ Role in Health Economics & Outcomes Research within Oncology

ID: POP-264


Features:

11 Info Graphics

12 Data Graphics

180+ Metrics

7 Narratives


Pages: 38


Published: Pre-2019


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As payers and consumers place increasing emphasis on positive outcomes for patients' health, organizations are developing their health outcomes data generation and utilization skills. The Medical Affairs (MA) function plays a vital role in health outcomes (HO) information exchange between biopharmaceutical companies and key external stakeholders.

Development of strong HO capabilities within MA organizations requires increase in MA’s involvement with HO groups, development of field-based HO capabilities, customization of HO data according to stakeholders, and building real world data capabilities to generate and utilize HO information.

Best Practices, LLC undertook a study to help companies focused on oncology therapies find better ways to develop successful Health Outcomes groups. This research delivers current data and best practices from Medical Affairs leaders with an oncology focus at top biopharmaceutical companies.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical


Companies Profiled:
Astellas; AstraZeneca; Bayer; Insys Therapeutics; Incyte; Jazz Pharmaceuticals; Lilly; Onyx Pharmaceuticals; ProStrakan; Roche

Study Snapshot

This study engaged 10 executives from leading life sciences companies. The analysis is focused on companies with oncology therapies.

Key Findings

· Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of the benchmark class; sixty percent of companies have had it in place for less than three years.
· Reporting Structure: 60% of companies’ HO groups report to Medical Affairs. A majority of the interviewed executives think that HO groups must report to a science and research oriented department such as clinical or medical affairs. Between these two, medical affairs provides better opportunities for needs assessment, communicating HO data insights, and interacting with key decision makers.

Table of Contents

§ Executive Summary pp. 3-9

    ü Research Objectives & Methodology pp. 3
    ü Participating Companies pp. 4
    ü Abbreviations pp. 5-6
    ü Key Findings & Insights pp. 7-9

§ Longevity of HO Groups pp. 10-11
§ HO Leadership pp. 12-13
§ HO Reporting Structure pp. 14-15
§ HO Group Staffing pp. 16-19
§ MA’s Role in HO Activities pp. 20-23
§ MA’s Role in Collecting HO Data pp. 24-25
§ Utilization of HO Data pp. 26-32
§ Impact of HO Data on Decisions pp. 33-36

List of Charts & Exhibits

· Length of Health Outcomes (HO) Programs
· HO Leadership Within Benchmark Class
· Reporting Structure: To whom does the Health Outcomes group(s) report?
· Number of Field and Office Based HO’s FTEs
· Percentage of Field-Based HO FTEs
· Core Field-Based HO Responsibilities
· Medical Affair’s Involvement in HO Activities
· Medical Affair’s Role in Collecting HO Data
· Utilizing the Health Outcomes Data To Inform Patients
· Utilizing the Health Outcomes Data To Inform Payers
· Utilizing the Health Outcomes Data To Inform Providers
· Effect of HO Data on Critical Decisions